GlobeNewswire Inc | May 20, 2021 04:30PM EDT

May 20, 2021

Heidelberg, Germany, May 20, 2021Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the Annual Meeting) will be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT). Due to the continuing COVID-19 pandemic and out of concern for the health and safety of shareholders and other attendees, the Annual Meeting will be held virtually and can be followed by visiting www.virtualshareholdermeeting.com/AFMD2021, in accordance with the instructions provided in the notice of the meeting. Shareholders will not be able to attend the Annual Meeting in person.

The notice and agenda of the Annual Meeting are available on Affimeds website at https://www.affimed.com/investors/ under Annual Meeting, as well as the SECs website at www.sec.gov.

About Affimed N.V.Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The companys proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE. Headquartered in Heidelberg, Germany, with offices in New York, New York, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients lives. For more about the companys people, pipeline and partners, please visit: www.affimed.com.

Investor Relations ContactAlexander FudukidisHead of Investor Relationsa.fudukidis@affimed.comTel.: +1 (917) 436-8102